Literature DB >> 1452667

Comparative study of antipneumocystis agents in rats by using a Pneumocystis carinii-specific DNA probe to quantitate infection.

P A Liberator1, J W Anderson, M Powles, L A Pittarelli, M Worley, M Becker-Hapak, D C Graves, D M Schmatz.   

Abstract

A repetitive genomic DNA clone (B12-2) that specifically hybridizes to Pneumocystis carinii DNA has been identified. No cross-hybridization to genomic DNA prepared from bacteria, other fungi, protozoa, or mammals was observed. Clone B12-2 is multiply represented in the P. carinii genome. By direct hybridization to DNA prepared from the lungs of immunosuppressed rats, the probe can detect the equivalent of fewer than 1,000 P. carinii organisms. A hybridization assay employing clone B12-2 has been developed to quantitate organism load in the rat model for P. carinii. Application of the assay to track the accumulation of organisms during the immunosuppression regimen as well as to monitor the efficacy of two drug therapies used clinically for the treatment of P. carinii pneumonia is described here. The clone B12-2 hybridization assay for the determination of P. carinii organism load possesses several advantageous features and thus should serve to complement conventional staining and immunohistochemical methods.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452667      PMCID: PMC270561          DOI: 10.1128/jcm.30.11.2968-2974.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  A self-splicing intron in the small subunit rRNA gene of Pneumocystis carinii.

Authors:  M L Sogin; J C Edman
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

3.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

4.  Pneumocystis carinii: growth variables and estimates in the A549 and WI-38 VA13 human cell lines.

Authors:  M T Cushion; J J Ruffolo; M J Linke; P D Walzer
Journal:  Exp Parasitol       Date:  1985-08       Impact factor: 2.011

5.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

6.  Activity of inosine analogs against Pneumocystis carinii in culture.

Authors:  M S Bartlett; J J Marr; S F Queener; R S Klein; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

7.  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; S Kuhn; S Chaudhary; S Feldman; M Verzosa; R J Aur; C Pratt; S L George
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

8.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

9.  Characterization and cloning of Pneumocystis carinii nucleic acid.

Authors:  M A Worley; M H Ivey; D C Graves
Journal:  J Protozool       Date:  1989 Jan-Feb

10.  Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.

Authors:  C S Taft; T Stark; C P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

View more
  5 in total

1.  Identification of extrapulmonary Pneumocystis carinii in immunocompromised rats by PCR.

Authors:  S Chary-Reddy; D C Graves
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

2.  Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.

Authors:  T J O'Leary; M M Tsai; C F Wright; M T Cushion
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

3.  Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats.

Authors:  M A Powles; D C McFadden; P A Liberator; J W Anderson; E B Vadas; D Meisner; D M Schmatz
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

4.  Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.

Authors:  M A Powles; P Liberator; J Anderson; Y Karkhanis; J F Dropinski; F A Bouffard; J M Balkovec; H Fujioka; M Aikawa; D McFadden; D Schmatz
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

5.  New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.

Authors:  D M Schmatz; M A Powles; D McFadden; K Nollstadt; F A Bouffard; J F Dropinski; P Liberator; J Andersen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.